Dr. Shah on Results Seen With Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

Video

Bijal Shah, MD, MS, discusses the results seen with brexucabtagne autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as demonstrated in the phase 2 ZUMA-3 trial.

Bijal Shah, MD, MS, an associate member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses the results seen with brexucabtagne autoleucel (formerly KTE-X19; Tecartus) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), as demonstrated in the phase 2 ZUMA-3 trial (NCT02614066).

Results from the trial demonstrated that the agent yielded a complete remission (CR) rate of approximately 56%, according to Shah. Additionally, these CRs translated into improvements in relapse-free survival, overall survival (OS), and duration of remission, which were well beyond the expectations of investigators, Shah says.

Moreover, in patients who achieved a CR/CR with incomplete blood count recovery (CRi), the median OS still has not been met, Shah adds. In this patient population, these results are quite remarkable, Shah concludes.


Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD